Current perspective of neuroprotection and glaucoma

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 2109-2118

  Tian, Kailin ^a,b   Shibata Germanos, Shannon ^a   Pahlitzsch, Milena ^a   Cordeiro, M Francesca ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Glaucoma; Neuroprotection; Retinal ganglion cell

Indexed keywords

AGMATINE; AMINOGUANIDINE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRIMONIDINE; CILIARY NEUROTROPIC FACTOR; ETANERCEPT; GINKGO BILOBA EXTRACT; MEMANTINE; NERVE GROWTH FACTOR; NEUROTROPIC AGENT; NILVADIPINE; TIMOLOL MALEATE; UBIDECARENONE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL LOSS; CELL SURVIVAL; CONTACT LENS; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; EMBRYONIC STEM CELL; EXCITOTOXICITY; GLAUCOMA; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INTRAOCULAR PRESSURE; LIPID PEROXIDATION; MULTICENTER STUDY (TOPIC); NERVE CELL; NEUROPROTECTION; NONHUMAN; OPTIC NERVE INJURY; OXIDATIVE STRESS; PERIMETRY; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA CELL; RETINA GANGLION CELL; REVIEW; SCHWANN CELL; STEM CELL TRANSPLANTATION; VISUAL IMPAIRMENT;

EID: 84947055095     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S80445     Document Type: Review

References (124)

1. Kingman S. Glaucoma is second leading cause of blindness globally. Bull World Health Organ. 2004;82(11):887-888.
2. Quigley HA, Broman AT. The number of people with glaucoma world­wide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267.
3. Kaushik S, Pandav SS, Ram J. Neuroprotection in glaucoma. J Postgrad Med. 2003;49(1):90.
4. Chang EE, Goldberg JL. Glaucoma 2.0: neuroprotection, neuroregenera­tion, neuroenhancement. Ophthalmology. 2012;119(5):979-986.
5. Dielemans I, Vingerling JR, Wolfs RCW, Hofman A, Grobbee DE, de Jong PTVM. The prevalence of primary open-angle glaucoma in a population-based study in the Netherlands: the Rotterdam study. Ophthalmology. 1994;101(11):1851-1855.
6. Leske MC, Wu SY, Hennis A, et al; BESs Study Group. Risk factors for incident open-angle glaucoma: the Barbados eye studies. Ophthalmology. 2008;115(1):85-93.
7. Bagnis A, Papadia M, Scotto R, Traverso CE. Current and emerging medical therapies in the treatment of glaucoma. Expert Opin Emerg Drugs. 2011;16(2):293-307.
8. Heijl A, Bengtsson B, Hyman L, Leske MC; Early Manifest Glaucoma Trial Group. Natural history of open-angle glaucoma. Ophthalmology. 2009;116(12):2271-2276.
9. Kolko M. Present and new treatment strategies in the management of glaucoma. Open Ophthalmol J. 2015;9:89-100.
10. Higginbotham EJ. Considerations in glaucoma therapy: fixed com­binations versus their component medications. Clin Ophthalmol. 2010;4(1):1-9.
11. Casson RJ, Chidlow G, Ebneter A, Wood JP, Crowston J, Goldberg I. Translational neuroprotection research in glaucoma: a review of definitions and principles. Clin Exp Ophthalmol. 2012;40(4): 350-357.
12. Emre E, Yüksel N, Duruksu G, et al. Neuroprotective effects of intravitreally transplanted adipose tissue and bone marrow-derived mesenchymal stem cells in an experimental ocular hypertension model. Cytotherapy. 2015;17(5):543-559.
13. Sena DF, Ramchand K, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2010;2:CD006539.
14. O’Neill EC, Mackey DA, Connell PP, Hewitt AW, Danesh-Meyer HV, Crowston JG. The optic nerve head in hereditary optic neuropathies. Nat Rev Neurol. 2009;5(5):277-287.
15. Osborne NN, Ugarte M, Chao M, et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol. 1999;43:S102-S128.
16. Izzotti A, Bagnis A, Saccà SC. The role of oxidative stress in glaucoma. Mutat Res. 2006;612(2):105-114.
17. Quigley HA, McKinnon SJ, Zack DJ, et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Investig Ophthalmol Vis Sci. 2000;41(11):3460-3466.
18. D’hondt C, Srinivas SP, Vereecke J, Himpens B. Adenosine opposes thrombin-induced inhibition of intercellular calcium wave in corneal endothelial cells. Invest Ophthalmol Vis Sci. 2007;48(4):1518-1527.
19. Kuehn MH, Kim CY, Ostojic J, et al. Retinal synthesis and deposition of complement components induced by ocular hypertension. Exp Eye Res. 2006;83(3):620-628.
20. Dreyer EB. A proposed role for excitotoxicity in glaucoma. J Glaucoma. 1998;7(1):62-67.
21. Michaelis EK. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog Neurobiol. 1998;54(4):369-415.
22. Massey SC, Redburn DA. Transmitter circuits in the vertebrate retina. Prog Neurobiol. 1987;28(1):55-96.
23. Dkhissi O, Chanut E, Wasowicz M, et al. Retinal TUNEL-positive cells and high glutamate levels in vitreous humor of mutant quail with a glaucoma-like disorder. Investig Ophthalmol Vis Sci. 1999;40:990-994.
24. Song W, Huang P, Zhang C. Neuroprotective therapies for glaucoma. Drug Des Devel Ther. 2015;9:1469-1479.
25. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114(3):299-305.
26. Brooks DE, Garcia GA, Dreyer EB, Zurakowski D, Franco-Bourland RE. Vitreous body glutamate concentration in dogs with glaucoma. Am J Vet Res. 1997;58(8):864-867.
27. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol. 2009;87(4):450-454.
28. Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and meman­tine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014;311(1):33-44.
29. Gabelt BT, Rasmussen CA, Tektas OY, et al. Structure/function studies and the effects of memantine in monkeys with experimental glaucoma. Investig Ophthalmol Vis Sci. 2012;53(4):2368-2376.
30. Mayama C. Calcium channels and their blockers in intraocular pressure and glaucoma. Eur J Pharmacol. 2013;739:96-105.
31. Takahashi K, Lam TT, Edward DP, Buchi ER, Tso MOM. Protec­tive effects of flunarizine on ischemic injury in the rat retina. Arch Ophthalmol. 1992;110(6):862-870.
32. Koseki N, Araie M, Tomidokoro A, et al. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure. Ophthalmology. 2008;115(11): 2049-2057.
33. Poo M. Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2001;2(1):24-32.
34. Yan Q, Wang J, Matheson CR, Urich JL. Glial cell line - derived neurotrophic factor (GDNF) promotes the survival of axotomized retinal ganglion cells in adult rats: comparison to and combination with brain-derived neurotrophic factor (BDNF). J Neurobiol. 1999;38(3):382-390.
35. Ko M-L, Hu D-N, Ritch R, Sharma SC, Chen C-F. Patterns of retinal ganglion cell survival after brain-derived neurotrophic factor admin­istration in hypertensive eyes of rats. Neurosci Lett. 2001;305(2): 139-142.
36. Fu QL, Li X, Yip HK, et al. Combined effect of brain-derived neu­rotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. Neuroscience. 2009; 162(2):375-382.
37. Parrilla-Reverter G, Agudo M, Sobrado-Calvo P, Salinas-Navarro M, Villegas-Pérez MP, Vidal-Sanz M. Effects of different neurotrophic factors on the survival of retinal ganglion cells after a complete intraorbital nerve crush injury: a quantitative in vivo study. Exp Eye Res. 2009;89(1):32-41.
38. Ji JZ, Elyaman W, Yip HK, et al. CNTF promotes survival of retinal ganglion cells after induction of ocular hypertension in rats: the pos­sible involvement of STAT3 pathway. Eur J Neurosci. 2004;19(2):265-272.
39. Cheng L, Sapieha P, Kittlerová P, Hauswirth WW, Di Polo A. TrkB gene transfer protects retinal ganglion cells from axotomy-induced death in vivo. J Neurosci. 2002;22(10):3977-3986.
40. Checa-Casalengua P, Jiang C, Bravo-Osuna I, et al. Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure. J Control Release. 2011;156(1):92-100.
41. Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108(15):6241-6245.
42. Lambiase A, Aloe L, Centofanti M, et al. Experimental and clini­cal evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. Proc Natl Acad Sci U S A. 2009;106(32):13469-13474.
43. Miyazaki M, Ikeda Y, Yonemitsu Y, et al. Pigment epithelium-derived factor gene therapy targeting retinal ganglion cell injuries: neuroprotec­tion against loss of function in two animal models. Hum Gene Ther. 2010;22(5):559-565.
44. Akman A, Cetinkaya A, Akova YA, Ertan A. Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol - dorzolamide combination. Eye. 2005;19(2):145-151.
45. Levkovitch-Verbin H, Harris-Cerruti C, Groner Y, Wheeler LA, Schwartz M, Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Investig Ophthalmol Vis Sci. 2000;41(13):4169-4174.
46. Wheeler LA, Gil DW, WoldeMussie E. Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol. 2001;45:S290-S294.
47. Semba K, Namekata K, Kimura A, Harada C, Mitamura Y, Harada T. Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma. Cell Death Dis. 2014;5(7):e1341.
48. Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol. 2011;151(4):671-681.
49. De Moraes CG, Liebmann JM, Greenfield DS, Gardiner SK, Ritch R, Krupin T. Risk factors for visual field progression in the low-pres­sure glaucoma treatment study. Am J Ophthalmol. 2012;154(4): 702-711.
50. Kolomeyer AM, Zarbin MA. Trophic factors in the pathogen­esis and therapy for retinal degenerative diseases. Surv Ophthalmol. 2014;59(2):134-165.
51. Cuenca N, Fernández-Sánchez L, Campello L, et al. Cellular responses following retinal injuries and therapeutic approaches for neurodegenera­tive diseases. Prog Retin Eye Res. 2014;43:1-59.
52. Izzotti A, Saccà SC, Cartiglia C, De Flora S. Oxidative deoxyribo­nucleic acid damage in the eyes of glaucoma patients. Am J Med. 2003; 114(8):638-646.
53. Saccà SC, Pascotto A, Camicione P, Capris P, Izzotti A. Oxidative DNA damage in human trabecular meshwork and its correlation with intraocular pressure and visual field in primary open angle glaucoma. Arch Ophthalmol. 2005;123:458-463.
54. Neufeld AH. Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma. Brain Res Bull. 2004;62(6):455-459.
55. Birich TV, Birich TA, Marchenko LN, Remizonova DN, Fedylov AS. [Vitamin E in the complex treatment of patients with primary glaucoma]. Vestn Oftalmol. 1985;102(2):10-13.
56. Cellini M, Caramazza N, Mangiafico P, Possati GL, Caramazza R. Fatty acid use in glaucomatous optic neuropathy treatment. Acta Ophthalmol Scand. 1998;76(S227):41-42.
57. Buschini E, Fea AM, Lavia CA, et al. Recent developments in the management of dry age-related macular degeneration. Clin Ophthalmol. 2015;9:563-574.
58. Ko M-L, Peng P-H, Hsu S-Y, Chen C-F. Dietary deficiency of vitamin E aggravates retinal ganglion cell death in experimental glaucoma of rats. Curr Eye Res. 2010;35(9):842-849.
59. Hsu KH, de la Jara PL, Ariyavidana A, et al. Release of betaine and dexpanthenol from vitamin E modified silicone-hydrogel contact lenses. Curr Eye Res. 2014;40(3):267-273.
60. Hsu K-H, Carbia BE, Plummer C, Chauhan A. Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy. Eur J Pharm Biopharm. 2015;94:312-321.
61. DeFeudis FV. Ginkgo Biloba Extract (EGb 761): Pharmacological Activities and Clinical Applications. Paris: Elsevier; 1991.
62. Detry-Morel M. Prospects in the medical treatment of glaucomatous neuropathy. Basics of neuroprotection. J Fr Ophtalmol. 1999;22(1): 122.
63. Cybulska-Heinrich AK, Mozaffarieh M, Flammer J. Ginkgo biloba: an adjuvant therapy for progressive normal and high tension glaucoma. Mol Vis. 2012;18:390.
64. Beal MF. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors. 1999;9(2-4):261-266.
65. Nucci C, Tartaglione R, Cerulli A, et al. Retinal damage caused by high intraocular pressure - induced transient ischemia is prevented by coenzyme Q10 in rat. Int Rev Neurobiol. 2007;82:397-406.
66. Nakajima Y, Inokuchi Y, Nishi M, Shimazawa M, Otsubo K, Hara H. Coenzyme Q 10 protects retinal cells against oxidative stress in vitro and in vivo. Brain Res. 2008;1226:226-233.
67. Parisi V, Centofanti M, Gandolfi S, et al. Effects of coenzyme Q10 in conjunction with vitamin E on retinal-evoked and cortical-evoked responses in patients with open-angle glaucoma. J Glaucoma. 2014; 23(6):391-404.
68. Tezel G. Immune regulation toward immunomodulation for neuropro­tection in glaucoma. Curr Opin Pharmacol. 2013;13(1):23-31.
69. Tezel G. The immune response in glaucoma: a perspective on the roles of oxidative stress. Exp Eye Res. 2011;93(2):178-186.
70. Wax MB, Tezel G. Immunoregulation of retinal ganglion cell fate in glaucoma. Exp Eye Res. 2009;88(4):825-830.
71. Tezel G. The role of glia, mitochondria, and the immune system in glaucoma. Invest Ophthalmol Vis Sci. 2009;50(3):1001-1012.
72. Naskar R, Wissing M, Thanos S. Detection of early neuron degeneration and accompanying microglial responses in the retina of a rat model of glaucoma. Investig Ophthalmol Vis Sci. 2002;43(9):2962-2968.
73. Tezel G, Li LY, Patil RV, Wax MB. TNF- and TNF-receptor-1 in the retina of normal and glaucomatous eyes. Investig Ophthalmol Vis Sci. 2001;42(8):1787-1794.
74. McKinnon SJ. The cell and molecular biology of glaucoma: common neurodegenerative pathways and relevance to glaucoma. Invest Oph­thalmol Vis Sci. 2012;53(5):2485-2487.
75. Wax MB, Tezel G, Yang J, et al. Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived fas-ligand. J Neurosci. 2008;28(46): 12085-12096.
76. Hong S, Park K, Kim CY, Seong GJ. Agmatine inhibits hypoxia-induced TNF-alpha release from cultured retinal ganglion cells. Biocell. 2008;32(2):201-205.
77. Hong S, Kim CY, Lee WS, Shim J, Yeom HY, Seong GJ. Ocular hypotensive effects of topically administered agmatine in a chronic ocular hypertensive rat model. Exp Eye Res. 2010;90(1):97-103.
78. Roh M, Zhang Y, Murakami Y, et al. Etanercept, a widely used inhibitor of tumor necrosis factor-α (TNF-α), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One. 2012;7(7):e40065.
79. Bringmann A, Grosche A, Pannicke T, Reichenbach A. GABA and glutamate uptake and metabolism in retinal glial (Müller) cells. Front Endocrinol. 2013;4:48.
80. Wang L, Cioffi GA, Cull G, Dong J, Fortune B. Immunohistologic evidence for retinal glial cell changes in human glaucoma. Invest Ophthalmol Vis Sci. 2002;43(4):1088-1094.
81. Neufeld AH. Microglia in the optic nerve head and the region of parapapillary chorioretinal atrophy in glaucoma. Arch Ophthalmol. 1999;117(8):1050-1056.
82. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by. Invest Ophthalmol. 1995;36(April):774-786.
83. Cordeiro MF, Guo L, Coxon KM, et al. Imaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo. Cell Death Dis. 2010;1(1):e3.
84. McKinnon SJ, Lehman DM, Tahzib NG, et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther. 2002;5(6):780-787.
85. Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature. 2006;441(7097):1068-1074.
86. Johnson TV, Bull ND, Martin KR. Stem cell therapy for glaucoma: possibilities and practicalities. Expert Rev Ophthalmol. 2011;6(2): 165-174.
87. Bull ND, Martin KR. Using stem cells to mend the retina in ocular disease. Regen Med. 2009;4(6):855-864.
88. Liton PB, Challa P, Stinnett S, Luna C, Epstein DL, Gonzalez P. Cel­lular senescence in the glaucomatous outflow pathway. Exp Gerontol. 2005;40(8):745-748.
89. Du Y, Roh DS, Mann MM, Funderburgh ML, Funderburgh JL, Schuman JS. Multipotent stem cells from trabecular meshwork become phagocytic TM cells. Invest Ophthalmol Vis Sci. 2012;53(3): 1566-1575.
90. Du Y, Yun H, Yang E, Schuman JS. Stem cells from trabecular mesh­work home to TM tissue in vivo. Investig Ophthalmol Vis Sci. 2013; 54(2):1450-1459.
91. Manuguerra-Gagné R, Boulos PR, Ammar A, et al. Transplantation of mesenchymal stem cells promotes tissue regeneration in a glaucoma model through laser-induced paracrine factor secretion and progenitor cell recruitment. Stem Cells. 2013;31(6):1136-1148.
92. Meyer JS, Katz ML, Maruniak JA, Kirk MD. Embryonic stem cell-derived neural progenitors incorporate into degenerating retina and enhance survival of host photoreceptors. Stem Cells. 2006;24(2): 274-283.
93. Vugler A, Lawrence J, Walsh J, et al. Embryonic stem cells and retinal repair. Mech Dev. 2007;124(11):807-829.
94. Chen M, Chen Q, Sun X, et al. Generation of retinal ganglion - like cells from reprogrammed mouse fibroblasts. Invest Ophthalmol Vis Sci. 2010;51(11):5970-5978.
95. Jagatha B, Divya MS, Sanalkumar R, et al. In vitro differentiation of retinal ganglion-like cells from embryonic stem cell derived neural progenitors. Biochem Biophys Res Commun. 2009;380(2):230-235.
96. Bull ND, Johnson TV, Martin KR. Stem cells for neuroprotection in glaucoma. Prog Brain Res. 2008;173(08):511-519.
97. Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D. Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases. Isr Med Assoc J. 2009;11(4):201-204.
98. Guo L, Davis B, Nizari S, et al. Direct optic nerve sheath (DONS) application of Schwann cells prolongs retinal ganglion cell survival in vivo. Cell Death Dis. 2014;5(10):e1460.
99. Sadan O, Bahat-Stromza M, Barhum Y, et al. Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev. 2009;18(8):1179-1190.
100. Levkovitch-Verbin H, Sadan O, Vander S, et al. Intravitreal injec­tions of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transection. Invest Ophthalmol Vis Sci. 2010;51(12):6394-6400.
101. Flachsbarth K, Kruszewski K, Jung G, et al. Neural stem cell-based intraocular administration of ciliary neurotrophic factor attenuates the loss of axotomized ganglion cells in adult mice. Invest Ophthalmol Vis Sci. 2014;55(11):7029-7039.
102. Schwartz M, Yoles E. Neuroprotection: a new treatment modality for glaucoma? Curr Opin Ophthalmol. 2000;11(2):107-111.
103. Medeiros FA, Alencar LM, Zangwill LM, Sample PA, Weinreb RN. The relationship between intraocular pressure and pro­gressive retinal nerve fiber layer loss in glaucoma. Ophthalmology. 2009;116(6):1125-1133.
104. Harwerth RS, Carter-Dawson L, Smith EL, Barnes G, Holt WF, Crawford MLJ. Neural losses correlated with visual losses in clinical perimetry. Invest Ophthalmol Vis Sci. 2004;45(9):3152-3160.
105. Kerrigan-Baumrind LA, Quigley HA, Pease ME, Kerrigan DF, Mitchell RS. Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. Invest Ophthalmol Vis Sci. 2000;41(3):741-748.
106. Medeiros FA, Lisboa R, Weinreb RN, Liebmann JM, Girkin C, Zangwill LM. Retinal ganglion cell count estimates associated with early development of visual field defects in glaucoma. Ophthalmology. 2013;120(4):736-744.
107. Bussel II, Wollstein G, Schuman JS. OCT for glaucoma diagnosis, screening and detection of glaucoma progression. Br J Ophthalmol. 2013;98(suppl 2):ii15-ii19.
108. El Chehab H, Delbarre M, Maréchal M, et al. [New neuroretinal rim analysis with spectral domain optical coherence tomography, spectralis (Heidelberg Engineering, Germany). Preliminary study]. J Fr Ophtalmol. 2015;38(1):46-52.
109. Friedlander RM. Apoptosis and caspases in neurodegenerative dis­eases. N Engl J Med. 2003;348(14):1365-1375.
110. Bizrah M, Dakin SC, Guo L, et al. A semi-automated technique for labeling and counting of apoptosing retinal cells. BMC Bioinformatics. 2014;15(1):169.
111. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry. 1998;31(1):1-9.
112. Carroll AD, Moyen C, Van Kesteren P, Tooke F, Battey NH, Brownlee C. Ca2+, annexins, and GTP modulate exocytosis from maize root cap protoplasts. Plant Cell. 1998;10(8):1267-1276.
113. Meers P, Mealy T. Calcium-dependent annexin V binding to phos­pholipids: stoichiometry, specificity, and the role of negative charge. Biochemistry. 1993;32(43):11711-11721.
114. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A. 1998;95(11):6349-6354.
115. Flotats A, Carrió I. Non-invasive in vivo imaging of myocardial apoptosis and necrosis. Eur J Nucl Med Mol Imaging. 2003;30(4): 615-630.
116. Yang DJ, Azhdarinia A, Wu P, et al. In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-annexin V. Cancer Biother Radiopharm. 2001;16(1):73-83.
117. Horisberger K, Erben P, Ströbel P, et al. Annexin and survivin in locally advanced rectal cancer: indicators of resistance to preoperative chemoradiotherapy? Onkologie. 2010;33(8-9):439-444.
118. Cordeiro MF, Guo L, Luong V, et al. Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc Natl Acad Sci U S A. 2004;101(36):13352-13356.
119. Cordeiro MF, Migdal C, Bloom P, Fitzke FW, Moss SE. Imaging apoptosis in the eye. Eye (Lond). 2011;25(5):545-553.
120. Guo L, Moss SE, Alexander RA, Ali RR, Fitzke FW, Cordeiro MF. Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest Ophthalmol Vis Sci. 2005;46(1):175.
121. Guo L, Salt TE, Maass A, et al. Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo. Invest Ophthalmol Vis Sci. 2006;47(2):626.
122. Guo L, Salt TE, Luong V, et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci U S A. 2007;104(33):13444-13449.
123. Schmitz-Valckenberg S, Guo L, Maass A, et al. Real-time in vivo imag­ing of retinal cell apoptosis after laser exposure. Invest Ophthalmol Vis Sci. 2008;49(6):2773.
124. Prevention of blindness and visual impairment: Priority eye diseases. World Health Organization. Available from: http://www.who.int/blindness/causes/priority/en/index9.html. Accessed October 16, 2015.